Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Incyte Pins Hopes On Phase III Jakafi Analysis In COVID-19 ARDS

Phase III Overall Negative, But Successful On Subset And Post-Hoc Analyses

Executive Summary

Drugs for ARDS in COVID-19 have yielded mixed results in the clinic, with Boehringer Ingelheim pulling one from Phase II development earlier this month.

You may also be interested in...

Humanigen Data Show Success In High-Risk COVID-19 Population

Phase III results show benefit in cytokine-release syndrome, while other drugs for treating patients hospitalized with COVID-19 have produced mixed results.

Coronavirus Update: How Vaccines Stack Up Against Variants So Far

Plus: Sanofi is getting into the mRNA vaccine game under a partnership with Translate Bio but has a lot of catching up to do.

Novartis’s JAK Inhibitor Fails In COVID, Raising Questions On Lilly Prospects

The Phase III failure of ruxolotinib contrasts with encouraging results and emergency use authorization for Lilly’s JAK inhibitor baricitinib in combination therapy.


Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts